MedElevator
Войти в исследования Frontiers in oncology · 2026
Epithelial-myoepithelial carcinoma of the nasopharynx: cases report and literature review.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xiong Wenju, Yin Lijuan, Wu NaNa, Xiang Zhongzheng, Wang Jun, Zeng Yuanyuan, Wei Xiaoyuan, Dai Zelei, Tan Chenfeng, Liu Lei
Аннотация
BACKGROUND: Epithelial-myoepithelial carcinoma (EMCa) is a low-grade malignant tumor that occurs primarily in the salivary glands. Its occurrence in the nasopharynx is exceedingly rare. Due to its scarcity, there is currently a lack of standardized treatment protocols, and robust prognostic data remain limited.
METHODS: We report a case series of two patients with histopathologically confirmed nasopharyngeal EMCa, supplemented by a systematic literature review to summarize its clinicopathological characteristics, treatment modalities, and prognostic factors.
RESULTS: The two cases exhibited strikingly divergent outcomes. The first patient (Case 1) underwent surgical resection followed by adjuvant radiotherapy, achieving a complete clinical response and remaining disease-free at 31 months. In contrast, the second patient (Case 2) presented a markedly more aggressive profile, characterized by younger age, neurological symptoms, and an atypically high 18F-FDG uptake on PET/CT, a notable deviation from the typically non-significant avidity reported for EMCa. Despite aggressive multimodal therapy, the disease progressed rapidly with extensive metastases. Subsequent institution of a combined chemotherapy and immunotherapy regimen successfully achieved disease stabilization.
CONCLUSION: Our cases illustrate the heterogeneous clinical behavior of nasopharyngeal EMCa, ranging from indolent disease to aggressive progression. Our observations suggest that high 18F-FDG uptake may serve as a critical biomarker for an aggressive phenotype. Given this variability, individualized treatment strategies may be warranted, and further studies are needed to better define optimal management for this rare tumor.
METHODS: We report a case series of two patients with histopathologically confirmed nasopharyngeal EMCa, supplemented by a systematic literature review to summarize its clinicopathological characteristics, treatment modalities, and prognostic factors.
RESULTS: The two cases exhibited strikingly divergent outcomes. The first patient (Case 1) underwent surgical resection followed by adjuvant radiotherapy, achieving a complete clinical response and remaining disease-free at 31 months. In contrast, the second patient (Case 2) presented a markedly more aggressive profile, characterized by younger age, neurological symptoms, and an atypically high 18F-FDG uptake on PET/CT, a notable deviation from the typically non-significant avidity reported for EMCa. Despite aggressive multimodal therapy, the disease progressed rapidly with extensive metastases. Subsequent institution of a combined chemotherapy and immunotherapy regimen successfully achieved disease stabilization.
CONCLUSION: Our cases illustrate the heterogeneous clinical behavior of nasopharyngeal EMCa, ranging from indolent disease to aggressive progression. Our observations suggest that high 18F-FDG uptake may serve as a critical biomarker for an aggressive phenotype. Given this variability, individualized treatment strategies may be warranted, and further studies are needed to better define optimal management for this rare tumor.